Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.
about
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance PAntifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemiaAntifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lysSafety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbitsNew perspectives in the diagnosis of systemic fungal infections.Effects of the hematoregulatory peptide SK&F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits.Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits.Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans.Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Towards a targeted, risk-based, antifungal strategy in neutropenic patients.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds.Opportunistic infections after blood and marrow transplantation.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelMurine model for Fusarium oxysporum invasive fusariosis reveals organ-specific structures for dissemination and long-term persistenceClinical pharmacology of antifungal agents in pediatric patients.Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.Oxidative burst and phagocytosis of neonatal neutrophils confronting Candida albicans and Candida parapsilosis.Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.Combination therapy for the treatment of pulmonary mold infections.Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategyFive-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival.Interdigital intertrigo due to Fusarium oxysporum.Antifungal therapy in 'bone marrow failure'.Characterization of cerebrosides from the thermally dimorphic mycopathogen Histoplasma capsulatum: expression of 2-hydroxy fatty N-acyl (E)-Delta(3)-unsaturation correlates with the yeast-mycelium phase transition.Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion.Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management.Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.Glycosphingolipids of the model fungus Aspergillus nidulans: characterization of GIPCs with oligo-alpha-mannose-type glycans.A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid.Newer antifungal agents.Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.Effect of amphotericin B lipid complex (ABLC) in very low birth weight infants.Recent Advances in the Treatment of Scedosporiosis and Fusariosis.
P2860
Q24535844-7C4E53AF-783C-48FA-853E-68230DDC50B5Q28349552-B02A5549-3078-4F50-B074-6B5E814F8798Q28369150-10314651-A33D-47D5-9987-1F5355E81B5DQ30596268-84B07111-D983-43E1-B351-34865E921D42Q30660609-A1106EB9-3B3B-44B2-8E7B-A67F0E53ADFAQ31161843-13F25A17-645C-4CAB-834E-A89A6B8A4332Q33697079-21DC7360-2AC5-4636-9462-33902E0834BBQ33697110-6085811E-0C05-47BA-99DE-759A1B14BE5EQ33699946-9DB1D30D-1738-4ADF-8D9C-D9F741AE6631Q33780702-E7A6492B-5DDC-4227-8683-74752DEE291CQ33977593-8B1270C3-B931-4F84-A467-F3EE3186C338Q33980180-3F048C47-6050-42B0-9F2E-8688A31B8C7CQ33981130-5A6B94DF-1052-4971-B2B6-36FE66BFDAE5Q33983629-2451800F-A0AC-4F5E-85F9-A581B8AE3C56Q34022479-6B228FA3-F9B1-4311-BC47-87E036EE962BQ34104748-A57102F7-17F6-4D19-BF3A-CA3E7D76FADBQ34108880-E1FA2FBD-65F6-4097-8FCD-5C3C4810768CQ34152388-28D37586-8D6A-4418-88C9-A18E28697DD0Q34294774-F7176671-4C94-42FA-84C2-7D9611D9A6FBQ34680675-8CF4F91A-6016-4EF0-A70B-F047A792A6C8Q35108357-EE8E4640-D01D-4138-9369-72DB7EDE7B7EQ36968140-15E74551-A66C-40CD-803E-7B4CF3BBF1A0Q37119029-2E9E528F-9A6A-46A6-82C0-C84AE29A12FAQ37363805-7B72E4AD-8199-4973-BE79-C87ACCF19C21Q37889382-913CD7D7-996F-480F-8E23-E594701F1B2AQ38806932-7C2196D0-3C90-48CB-9F76-4AD14B0557B3Q39475550-DE002464-8D06-45F1-8B1E-C69880E7C06EQ40630645-4A7DE566-481C-4776-9403-107A89137D03Q40774815-5A98E198-B060-4CC8-983E-CCB7C0B6DC73Q41733799-7790B4C2-E43D-4032-AC3E-F779935249DFQ43565271-65D9A5F2-18B3-4AD3-8353-DE149C66FB05Q43831741-8F52B661-3D04-4E22-8807-A18DABCBEEDAQ44159617-F06FC019-3153-4E88-94B4-1C173B01A550Q44396642-2A1DE22E-E85D-41BC-BD2A-CD0FF520581DQ44552191-DCA67858-E70F-45EE-88C9-67069A5B1581Q44717183-FA56F2F2-0061-4CC2-898A-A6DE4528979FQ44855715-37AB69C8-B3B7-4053-B50F-10E38BA84F77Q45223627-757E34D8-B118-4999-B5D9-7BCE0906B967Q46322264-8EE5EF0A-5091-4B58-8D66-13D228C28E93Q55453637-EAF3E385-6CC5-4B1B-972B-C74115E8F755
P2860
Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Recent progress and current pr ...... tions in neutropenic patients.
@en
type
label
Recent progress and current pr ...... tions in neutropenic patients.
@en
prefLabel
Recent progress and current pr ...... tions in neutropenic patients.
@en
P2093
P1476
Recent progress and current pr ...... tions in neutropenic patients.
@en
P2093
P304
P356
10.1016/S0891-5520(05)70303-2
P577
1996-06-01T00:00:00Z